2020 - flashback in pandemic context


An extraordinary year for Nano4 Global - all objectives achieved and start of molecular diagnostics for CoVID-19.

Major year for NANO4

  • Submission of NANO4 TB to regulatory agency (platform first indication)
  • Started and developed CoVID-19 Diagnostic Service
  • Welcoming a new Team member – we are now 7 - including production, QC and R&D, in our new CoVID Diagnostic Service.
  • Awarded Seal of Excellence from H2020 - EIC Accelerator
  •  Nano4 Global teams up with IPHT - Leibniz (www.leibniz-ipht.de/en/institute/photonics-for-life.html) for the development of a optical system reader and awarded a ACTPHAST - H2020 Grant.
  • Celebrating our 5th anniversary on the 14th of December – great way to close 2020!
NANO4 Nanodiagnostics Platform
  • Nano4 Global is licensed by Regulatory Agency INFARMED as Manufacturer and Distributer of In Vitro Diagnostic
  • Successful conclusion of NANO4 TB validation
  • Submission of NANO4 TB regulatory dossier to INFARMED for approval in the process to be conferred the CE Mark
  • We continued validation of NANO4 CML
CoVID-19 Diagnostics Service
  • NANO4 Global awarded with P2020 grant to scale-up service in CoVID context
  • Registration at ERS (Health Regulatory Agency) NANO4 as a Diagnostic Lab following validation by INSA (Portuguese National Institute of Health)
  • Major customers attracted by NANO4 CoVID Service performance

Looking back at 2019, one thing is certain – What a year!
Nano4 became closer to its goal, to launch innovative nanotechnology based molecular diagnostic.

read more


News & Updates
  August  2022
-Nano4 Global is one of the 15 Biotech companies in Portugal that you should know
  July  2021
NANO4 in partnership with CUF Hospitals and Clinics network initiates validation of diagnostics platform for Chronic Myeloid Leukaemia